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Background: Evidence of the genetic association between CD36 candidate gene and the risk of metabolic
syndrome and its components has been inconsistent. This case–control study assessed the haplotype-tagged SNPs
from CD36 on the risk of metabolic syndrome and components.
Methods and results: We recruited 1,000 cases and age, gender-matched controls were randomly selected from
the participants with metabolic syndrome defined by International Diabetes Federation. Overall, the haplotype
tagged SNPs of CD36 gene were not related to the risk of metabolic syndrome. For individuals with normal
lipid levels, several SNPs were significantly associated with the triglycerides and HDL-cholesterol levels: Subjects
with rs3211848 homozygote had a higher triglyceride level (99.16 ± 2.61 mg/dL), compared with non-carriers
(89.27 ± 1.45 mg/dL, P = 0.001). In addition, compared with non-carriers, individuals with rs1054516 heterozygous
and homozygous genotypes had a significantly lower HDL-cholesterol (46.6 ± 0.46 mg/dL for non-carrier,
44.6 ± 0.36 mg/dL for heterozygous, and 44.3 ± 0.56 mg/dL for homozygous, P = 0.0008).
Conclusion: The CD36 gene variants were significantly associated with triglycerides and HDL-cholesterol
concentrations among ethnic Chinese in Taiwan.
Keywords: Metabolic syndrome, CD 36 gene polymorphismIntroduction
The CD36 is a glycoprotein located in membrane and
plays various cellular processes such as lipid transport,
immune regulation, coagulation and atherosclerosis [1],
and the CD36 structure is related to scavenger receptor
B1, and highly binds to oxidized LDL [2], which induced
atherosclerosis process. CD36 gene variants regulated
fatty acid metabolism and accumulation of fat and fat
metabolites, and may influence the risk of metabolic
syndrome and may be a target for further personalized
medicine screening [3].
Emerging evidence indicating that variation in the
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reproduction in any medium, provided the ormetabolic syndrome. Individuals with CD36 deficiency,
which is prevalent among Asians, were likely to have the
abnormal levels of triglycerides and HDL-cholesterol
[4,5]. In addition, genetic variants of CD36 were related
to acute myocardial infarction [6], type 2 diabetes [7,8],
metabolic syndrome components [9,10], fatty acids [9]
and adiponectin levels [11], and free fatty acids [12].
However, no special ethnic Chinese population was
reported and only modest effects have been identified
for variants of CD36 gene for metabolic syndrome, and
the associations for metabolic syndrome itself have often
been inconsistent. These inconsistent findings may be
attributed to inadequate information from CD36 gene.
In addition, the confounding effects by clinical and life-
style factors should be considered concurrently [13].
Therefore, we examined the association of common
variants of the CD36 gene with the metabolic syndrometd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ethnic Chinese adults, controlling for clinical and life-
style factors.
Methods
Study design and study participants
The study design was a case–control study design based
on 8,911 adult participants who were recruited from the
Health Management Center of one tertiary hospital from
January 2004 to December 2007 and all provided the
written informed consents with the study protocol being
reported elsewhere [14,15]. In brief, details of socioeco-
nomic status, along with medical and medication histor-
ies were collected by questionnaires, and standardized
clinical procedures were undertaken. We excluded the
participants with concurrent severe medical diseases
such as cancer and heart failure. The participants signed
informed consent forms, and the protocol was approved
by the Institutional Research Board of the National
Taiwan University Hospital.
Details of subjects’ medical histories such as medica-
tion, hospitalization and smoking status were included
in the structural questionnaires. Standardized proce-
dures for the physical examination, such as anthropo-
metric measures and blood pressure, were performed
[16,17]. Blood pressure was measured in a resting pos-
ition by standard procedure. Body mass index (BMI) and
standing height were measured with subjects dressed in
light clothing and barefoot. BMI was calculated as
weight (in kilograms)/square of height (in meters). Waist
circumference was measured midline between the low
costal margin and superior posterior iliac crest.
Laboratory measurements
Procedures for blood sampling and analytic methods
were as previously described [18,19]. In brief, a blood
sample was collected from each participant after at least
a 12 hours fasting. Serum total cholesterol levels were
measured using the CHOD-PAP method (Boehringer
Mannheim, Germany). HDL-C was measured following
precipitation of apolipoprotein B-containing lipopro-
teins with phosphotungstic acid and magnesium ions
(Boehringer Mannheim, Germany). Triglyceride concen-
trations were measured by the GPO-DAOS method
(Wako Co., Japan). All of the lipids mentioned above
were measured using a Hitachi 7450 automated analyzer
(Hitachi, Japan). LDL-C concentrations were calculated
using the Friedewald formula. All the measures of both
samples were carried out in a single hospital and the
coefficients of variation were less than 5%.
Case ascertainment and matched control selection
We have recruited the participants from the matched
case–control design during 2003 and 2007. We randomlyselecting from 8,911 participants recruited from the
Health Management Center and all participants provided
written informed consent. We used International Dia-
betes Federation (IDF) criterion to define the metabolic
syndrome cases. The IDF criterion included central obes-
ity and other two components including high blood pres-
sure, dyslipidemia and high glucose levels which were
defined as: blood pressure of at least 130/85 mmHg or
undergoing treatment for hypertension (39%); serum tri-
glyceride of at least 150 mg/dL (25%); HDL cholesterol
of <40 mg/dL in men and <50 mg/dL in women (53%);
fasting glucose of 100 mg/dL or more (20%); and central
obesity, waist circumference greater than 90 cm in men
and 80 cm in women (38%). A total of 1000 cases of
metabolic syndrome were randomly selected. In addition,
the 1:1 matched control subjects were selected in the
same samples, with frequency-matched according to age
and gender.DNA genotyping & polymorphism detection
Three primers were designed for each SNP detection
with web-based software provided at Beckman Coulter
Inc (www.autoprimer.com). A forward and areverse PCR
primers were used to amplify a short stretch of DNA
(90 bp) covering the SNP of interest, and a tagged SNP
primer for single base primer extension to identify the
SNP. The 5' portion of the tagged primer is complemen-
tary to one of 12 unique single stranded DNA oligonu-
cleotides that are spotted at a specific location within
each well of a 384-well microplate. The 3' portion of the
tagged primer is complementary and precisely adjacent
to the SNP, which enables detection of the presence of
the SNP through the incorporation of a fluorescent-
labeled terminating nucleotide. The genotyping were
performed in a 12-plex PCR reaction of a 384-well plate
with the GenomeLab SNPstream genotyping platform
(Beckman Coulter Inc. Fullerton, CA) and its accom-
panying SNPstream software suite. The PCR reaction
was carried out in a total volume of 5 μl containing
75 μM dNTPs (Applied Biosystem), 5 mM MgCl2,
50 nM each primer, 2 ng of template DNA, and 0.1 U/μL
Taq Gold (Applied Biosystem). The cycling conditions
(MJ-225 thermal cycler) were 94°C for 1 minute followed
by 39 cycles of 94°C for 30 seconds, 55°C for 30 seconds,
and 72°C for 1 minute. After PCR reaction, the amplified
DNA fragments were treated with a clean-up cocktail of
exonuclease I and shrimp alkaline phosphatase to degrade
unincorporated PCR primers and deoxynucleotide tripho-
sphates. The reactions were carried out by adding 3 μl of
a mixture containing 0.67 U Exonuclease I (Amersham
Pharmacia, Buckinghamshire, UK) and 0.33 U shrimp
alkaline phosphatase (Amersham Pharmacia) to each well.
The plates were sealed and incubated for 30 min at 37°C
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was carried out with ‘cleaned’ PCR products as template
and a mixture of 12 site-specific SNP primers. The multi-
plex primer SNP extension reaction was performed in a
total volume of 7 μl containing 3.76 μl SNP extension
dilation buffer, 0.06 μl SNP primer mix (each 5 μM),
0.2 μl C/T (or C/G, T/C et al.) extension mix, 2.96 μl
water, and 0.02 μl SNPware DNA polymerase. The cycling
conditions were 96°C for 3 minutes followed by 45 cycles
of 94°C for 20 seconds, and 40°C for 11 seconds. The
tagged extension primers were extended with single
TAMRA- or fluorescein-labeled nucleotide and then
spatially resolved by hybridization to the complementary
oligonucleotides arrayed on the 384-well microplates
(SNPware Tag array). The Tag array plates were imaged
with a two-laser, two-color charged couple device-based
imager (GenomeLab SNPstream array imager). The 12
individual SNPs were identified by their position and
fluorescent color in each well according to the position of
the tagged oligonucleotides. Sample genotype data were
generated on the basis of the relative fluorescent inten-
sities for each SNP. The image signals were then trans-
ferred to genotyping software that translated the images
of the arrays into genotype calls. The error rate on the
basis of blind replicates was 0.1 to 1% for the SNPs exam-
ined in the present study.
Using the common SNPs for Han Chinese were identi-
fied from the International HapMap Project (www.hap-
map.org), and we selected the tagged SNP for CD36
candidate gene, which contained 19 SNPs whose minor
allele frequency was more than 5%. Tagger program
was used to select haplotype-tagging SNPs (htSNPs)
based on the pairwise linkage disequilibrium relation-
ships (r2 = 0.8). The common SNP subset represented
the information from the remaining SNPs and was in
linkage disequilibrium within each block.Statistical analysis
All data were presented as mean and standard deviation
for continuous variables and contingency tables for cat-
egorical data and were listed by status of case patients
and control subjects. The chi-square tests were used to
access Hardy-Weinberg equilibrium among cases and
controls and the allele frequency was compared between
the cases of metabolic syndrome and control subjects.
Subgroup analysis based on gender and age was per-
formed for specific genotype. Relationships between
metabolic component quantitative variables were ana-
lyzed by multiple linear regression analysis adjusting for
age, gender in specific subjects within the normal ranges
of the metabolic syndrome cutoff values. False discovery
rate [20] were used to correct for the multiple compari-
son problems for the significant P value threshold as0.05. In addition, we investigated the association between
the genotypes of SNP rs1054516 and HDL cholesterol,
after controlling clinical and lifestyle factors in the mul-
tiple regression model.
The selected tagged SNPs spanning CD36 form one
“block” whose algorithm was developed by Gabriel and
colleagues[21], where blocks identified with the default
settings in the Haploview program were merged if they
have multiallelic D’ greater than 0.8 and the cumulative
frequency of common haplotypes (>5% frequency) in
the merged block is >80% [22]. Haplotype frequencies
were estimated by SAS/Genetics software using the
expectation-maximization algorithm and the results
were verified by the THESIAS program [23]. Pair-wise
linkage disequilibrium coefficients, Lewontin's D' and
correlation coefficients (r2) were estimated iteratively.
Haplotype-specific analyses assessing the association be-
tween haplotypes and the continuous lipid profiles, were
performed by THESIAS program, which is based on the
stochastic-estimation and maximization algorithm. The
likelihood ratio test for haplotype-phenotype association
was twice the difference between the log-likelihood
under the null (one haplotype) and the alternative (add-
itional haplotypes) model, and the chi-square with
haplotype numbers as degree of freedom. We examined
the global significance level in the multivariate adjusted
linear models, and specifically tested the haplotype
effects, compared with the most common haplotype for
reference.
Previous literature showed that the relative risk be-
tween CD36 SNP and the risk of metabolic syndrome
was 1.3 ~ 1.4, and the allele frequencies of SNPs were
0.10 to 0.25 [9-11]. Under the additive mode of inherit-
ance and the baseline risk for the metabolic syndrome
as 0.10, we estimated the power for genetic effect was
90% with the sample size of 1000 cases & 1000 matched
controls [24].Results
Basic distribution of case–control subjects
Excluding missing data and failed genotyping, a total of
962 cases and 938 controls provided full genotyping
data. The clinical distributions of clinical and metabolic
components among the study participants, specified by
metabolic syndrome are listed in Table 1. Compared
with control subjects, case patients were likely to have
the history of hypoglycemic and lipid lowering drug, a
higher smoking and lower sports activity habit. In
addition, compared with control subjects, case patients
were likely to have a higher BMI, waist, blood pressure,
fasting and postprandial glucose, glycated hemoglobin,
uric acid levels and a higher total and LDL cholesterol,
triglycerides, and lower HDL cholesterol levels.
Table 1 Clinical characteristics of the study participants according to the metabolic syndrome status
Control % Case % P
N = 938 N = 962
N N
Gender 0.60
Women 343 36.6 363 37.7
Men 595 63.4 599 62.3
Hypoglycemic drugs (Yes) 49 5.2 130 13.5 <.0001
Lipid lowering drugs (yes) 44 4.7 99 10.3 <.0001
Current smoker 132 14.1 173 18.0 0.020
Current drinker 539 57.5 545 56.7 0.72
Regular sports habit 669 71.3 636 66.1 0.014
Mean SD Mean SD
Age, yrs 54.5 10.6 55.1 10.6 0.22
Body mass index, kg/m2 22.7 2.3 27.1 3.0 <.0001
Waist circumference, cm 79.2 6.4 94.2 7.1 <.0001
Systolic blood pressure, mmHg 122.7 14.8 133.2 14.9 <.0001
Diastolic blood pressure, mmHg 72.9 9.8 79.2 10.3 <.0001
Total cholesterol, mg/dL 203.0 36.5 206.8 36.7 0.025
Triglycerides, mg/dL 115.0 74.3 177.6 103.8 <.0001
HDL cholesterol, mg/dL 43.2 9.8 38.5 7.0 <.0001
LDL cholesterol, mg/dL 116.4 31.6 124.7 32.7 <.0001
Fasting glucose, mg/dL 93.3 22.7 105.2 28.1 <.0001
Postprandial glucose, mg/dL 120.1 52.3 129.8 59.2 0.0002
Uric acid, mg/dL 6.1 1.5 6.6 1.6 <.0001
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syndrome status
A total of 19 common htSNPs of CD36 gene were
selected from the HapMap website (http://www.hapmap.
org) to further genotyping (Additional file 1: Table S1).
We randomly selected 200 cases/200 controls from the
study participants and genotyped these SNPs. From
the pilot genotyping results, we found that several
CD36 gene SNPs were associated with metabolic syn-
drome status and metabolic trait, including HDL, tri-
glycerides, body mass index, fasting glucose and
triglyceride levels (Additional file 1: Table S2). Finally, we
selected the 7 SNPs for completing genotyping work in
all subjects.
Table 2 shows the minor allele frequency in the
selected 7 SNPs for CD36 gene in the study participants,
call rates, and the Hardy-Weinberg equilibrium testing
for cases and controls. We found that the call rates were
satisfactory (>99%) and the Hardy-Weinberg equilibrium
was not rejected in all SNPs, implying the genotyping
quality was good. We cannot identify any SNP for a sig-
nificant association with the status of metabolic syn-
drome for all subjects and limited to < 55 years old,as well as gender, in any mode of inheritance, including
co-dominant, additive, dominant and recessive modes
(data not shown).
Our next strategy is to perform the genetic asso-
ciation between CD36 gene SNPs and various meta-
bolic syndrome components. Overall, the association
between SNPs and metabolic components were found
for triglycerides, HDL-cholesterol and blood pressure,
as well as postprandial glucose, glycated hemoglobin
and c-reactive protein. Among them, we found that
triglycerides, HDL-cholesterol, triglycerides vs. HDL-
cholesterol ratio, have the most significant level, and
the significant level was between rs1054516 and HDL-
cholesterol, with P < 0.001 in additive, dominant and
co-dominant inheritance of models. Other SNPs, in-
cluding rs3211849, rs17154258, rs3211869, rs3211958,
and rs3211817, were also significantly associated with
HDL-cholesterol (Table 3). The patterns were similar
for log(triglycerides), triglycerides vs. HDL ratios, and
the significance level was persistent after multiple
comparison adjustments, indicating the CD36 gene
variants were significantly associated with triglycerides
HDL-cholesterol, and systolic blood pressure. Figures 1,
Table 2 Allele frequency in the selected SNPs for the CD36 gene (Chromosome #7) in the study participants and the
Hardy-Weinberg equilibrium testing
rs# Allele Position MAF
Controls
Call rate HWE P value
Cases Cases Controls
rs3211849 A < G 80121259 0.350 0.368 99.6% 0.68 0.08
rs17154258 G < A 80134866 0.055 0.056 99.8% 0.76 0.53
rs3211869 A < T 80125088 0.288 0.287 99.7% 0.48 0.15
rs3211958 G < A 80142008 0.442 0.421 99.7% 0.51 1.00
rs3211817 G < T 80116043 0.351 0.348 99.6% 1.00 0.39
rs1054516 C < T 80122878 0.447 0.455 99.8% 0.70 0.23
Rs17154233 C < A 80131125 0.134 0.119 99.8% 0.42 0.64
MAF: minor allele frequency.
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on triglycerides, HDL-cholesterol and systolic blood
pressure from pairwise genotype comparisons: subjects
with rs3211848 homozygote had a higher triglycerides
level (99.16 ± 2.61 mg/dL), compared with non-carriersTable 3 Association study for CD36 gene variants and metabo
adjusted for age and gender, the numbers in bold shows the
#rs Log (Triglyceride)
Additive Dominant Recessive Co-domin
rs3211849 0.013 0.21 0.001 0.005
rs17154258 0.20 0.34 0.06 0.14
rs3211869 0.026 0.09 0.034 0.06
rs3211958 0.019 0.040 0.08 0.06
rs3211817 0.019 0.17 0.007 0.021
rs1054516 0.11 0.41 0.06 0.17
rs17154233 0.73 0.74 0.85 0.94
#rs HDL-C
Additive Dominant Recessive Co-domin
rs3211849 0.002 0.002 0.07 0.006
rs17154258 0.42 0.80 0.004 0.017
rs3211869 0.001 0.016 0.001 0.002
rs3211958 0.001 0.001 0.035 0.002
rs3211817 0.003 0.027 0.007 0.010
rs1054516 0.001 0.000 0.10 0.001
rs17154233 0.14 0.06 0.46 0.08
#rs log(TG/HDL-C)
Additive Dominant Recessive Co-domin
rs3211849 0.002 0.033 0.001 0.002
rs17154258 0.18 0.37 0.013 0.041
rs3211869 0.003 0.026 0.004 0.006
rs3211958 0.002 0.003 0.032 0.007
rs3211817 0.003 0.05 0.002 0.004
rs1054516 0.011 0.042 0.033 0.039
rs17154233 0.39 0.32 0.88 0.56(89.27 ± 1.45 mg/dL, P = 0.001). In addition, com-
pared with non-carriers, individuals with rs1054516
heterozygous and homozygous genotypes had a sig-
nificant lower HDL-cholesterol (46.6 ± 0.46 mg/dL for
non-carrier, 44.6 ± 0.36 mg/dL for heterozygous, andlic syndrome components in the “normal” subjects,
significant level (<0.05); Lipid Profiles & blood pressure
Total cholesterol
ant Additive Dominant Recessive Co-dominant
0.52 0.40 0.92 0.69
0.029 0.022 0.93 0.07
0.46 0.51 0.58 0.76
0.75 0.51 0.83 0.72
0.62 0.84 0.48 0.78
0.95 0.73 0.79 0.87
0.34 0.52 0.14 0.31
SBP
ant Additive Dominant Recessive Co-dominant
0.002 0.013 0.011 0.009
0.84 0.75 0.53 0.75
0.26 0.14 0.98 0.29
0.11 0.26 0.14 0.26
0.12 0.06 0.70 0.16
0.002 0.004 0.025 0.007
0.41 0.48 0.46 0.65
DBP
ant Additive Dominant Recessive Co-dominant
0.08 0.45 0.017 0.06
0.22 0.20 1.00 0.43
0.55 0.32 0.72 0.46
0.64 0.79 0.60 0.87
0.51 0.37 0.99 0.64
0.05 0.20 0.06 0.13
0.77 0.88 0.57 0.85
Figure 1 Impact of CD36 gene on triglycerides levels (mg/dL ± SE) from pairwise genotype comparisons. Adjusted mean triglycerides for
non-carriers (black bars), for heterozygous (gray bars) and subjects homozygous for the minor allele (white bars). Sample sizes (n for non-carriers,
heterozygous, and homozygous subjects for SNP (rs3211849), n = 383, 408, 119, for SNP (rs3211958), n = 305, 432, 174, and for SNPs (rs3211817)
n = 377, 416, 115, resulting co-dominant P-values as 0.004, 0.035, and 0.018.
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minant mode).
The clinical distribution of total participants, accord-
ing to the SNP rs1054516 genotype status was listed in
Additional file 1: Table S3. The distributions among
three genotypes were similar, except for HDL choles-
terol: compared with those with CC and TC genotype,
participants with TT genotypes had a higher HDL chol-
esterol level (P = 0.009).Figure 2 Impact of CD36 gene on HDL-cholesterol levels (mg/dL ± SE
HDL-cholesterol for non-carriers (black bars), for heterozygous (gray bars) a
sizes (n for non-carriers, heterozygous, and homozygous subjects for SNP (r
and for SNPs (rs3211869), n = 463, 363, 84, resulting co-dominant P-values aTable 4 showed the multiple regression models of
SNP rs1054516 genotypes and various clinical variables,
including age, gender, body mass index, metabolic syn-
drome status, smoking, drinking and sports activity, as
well as the hypoglycemic and lipid lowering drugs. The
estimates for SNP rs1054516, after controlling for mul-
tiple variables were significant: compared with TT geno-
type, TC and CC genotypes had lower HDL cholesterol
levels (−1.00±0.40 mg/dL between TC and TT, P = 0.012,) from pairwise genotype comparisons. Adjusted mean
nd subjects homozygous for the minor allele (white bars). Sample
s3211849), n = 383, 408, 119, for SNP (rs17154258),n = 813, 94, 4,
s 0.006, 0.017 and 0.002.
Figure 3 Impact of CD36 gene on HDL-cholesterol levels (mg/dL ± SE) from pairwise genotype comparisons. Adjusted mean
HDL-cholesterol for non-carriers (black bars), for heterozygous (gray bars) and subjects homozygous for the minor allele (white bars). Sample
sizes (n for non-carriers, heterozygous, and homozygous subjects for SNP (rs3211958), n = 305, 432, 174, for SNP (rs3211817), n = 377, 416, 115,
and for SNP (rs1054516), n = 281, 444, 187, resulting co-dominant P-values as 0.002, 0.010, and 0.0008.
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sides, we found that age, gender, body mass index, meta-
bolic syndrome status, drinking, and sports activity
status were related to HDL cholesterol levels.
Haplotype analysis frequencies and association study
with metabolic syndrome components
We performed the haplotypes analyses for the 7 SNPs
from the CD36 gene to assess the association betweenFigure 4 Impact of CD36 gene on systolic blood pressure (mmHg ± S
blood pressure for non-carriers (black bars), for heterozygous (gray bars) an
(n for non-carriers, heterozygous, and homozygous subjects for SNP (rs3211
Resulting co-dominant P-values as 0.009 and 0.007.these haplotypes and various continuous metabolic syn-
drome components. Table 5 lists the common haplotype
(frequency > =5%) and the multivariate adjusted continu-
ous traits, which showed significant reduction: individuals
carrying the second common haplotype (GAAGGTA, fre-
quency = 23.0%) had a significant level of HDL cholesterol
(adjusted mean, 23.8, 95% confidence interval[CI], 22.3
to 25.4 mg/dL), as compared to those with the most fre-
quent haplotype, AATATCA (26.7%, adjusted mean, 22.2,E) from pairwise genotype comparisons. Adjusted mean systolic
d subjects homozygous for the minor allele (white bars). Sample sizes
849), n = 621, 664, 207, and for SNP (rs1054516), n = 466, 720, 308,
Table 4 The estimated parameters, standard errors and significant levels from the multiple linear regression models
for HDL cholesterol levels in the study participants
Parameter Estimate Standard error P value
Intercept 55.3 1.9 <.0001
SNP rs1054516 CC vs. TT −1.19 0.49 0.015
TC vs. TT −1.00 0.40 0.012
age +1 yr 0.05 0.02 0.008
Sex Men vs. Women −6.76 0.41 <.0001
BMI +1 kg/m^2 −0.49 0.07 <.0001
Metabolic syndrome case vs. control −2.51 0.46 <.0001
Smoking Yes vs. No −0.51 0.51 0.31
Drinking habit Yes vs. No 1.07 0.37 0.004
Sports activity Frequent vs. No 1.45 0.39 0.0002
Hypoglycemic medication Yes vs. No −1.11 0.62 0.08
Lipid lowering medication Yes vs. No 0.99 0.68 0.15
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was similar for triglycerides and triglycerides with
regards to HDL-cholesterol ratio.
Discussion
Our study showed that the CD36 gene variants were
associated with triglycerides and HDL cholesterol con-
centrations among ethnic Chinese in Taiwan. We con-
structed the haplotypes of CD36 gene and extensively
checked the association of specific SNP rs1054516 and
other clinical variables with HDL cholesterol level. Our
study has provided the following clinical evidence. First,
the CD36 candidate gene is an important determinant of
HDL-cholesterol and triglycerides among individuals
with normal-range lipids. Second, the metabolic syn-
drome itself, does not relate to the CD36 gene poly-
morphism in our study.
The mechanism of the CD36 gene for the pathogenesis
of metabolic syndrome components has been proposed
as the following: First, in the CD36 knockout mice,







AATATCA 0.267 22.2 20.7 23.6
GAAGGTA 0.230 23.8 22.3 25.4
GATATTA 0.098 22.3 20.4 24.1
GATGTTC 0.076 23.2 21.3 25.1
AATGTCA 0.058 22.3 20.3 24.4
The order of polymorphisms on the haplotype according to CD36 SNPs.
*: adjusted for gender and age.
**: Compared with the most common haplotype.were found in muscle and adipose tissues [25]. Trans-
genic mice over-expression CD36 protein was found to
have reduced blood lipids [26]. The transgenic expres-
sion of CD36 in the hypertensive rat model showed the
decreased metabolic syndrome and insulin resistance
burden. Cell culture study on monocyte CD36 expres-
sion showed a 34% expression increase in type 2 diabetes
as compared with control subjects [27]. Second, in
human cells, the CD36 protein receptor has a highly af-
finity to HDL; however, human LDL bound poorly to
CD36 protein [28], indicating selective binding of CD36
protein to HDL, instead of to LDL. In addition, CD36 is
a receptor for oxidized LDL and plays a role in scaven-
ging LDL modified by oxidation and mediating the
atherosclerosis process [1]. The expression patterns of
CD36 gene in human tissues were up-regulated in
response to oxidized LDL [29]. Furthermore, CD36 pro-
tein facilitates a large fraction of fatty acid uptake and
CD36 deficiency in humans was reported defect in myo-
cardial cell fatty acid analog [25], and this effect on car-
diac triglycerides storage was enhanced in obese statusions with continuous metabolic factors among the
Mean 95% CI P**P**
log (TG vs. HDL)
0.312 0.236 0.388
0.0001 0.246 0.164 0.328 0.006
0.86 0.330 0.234 0.426 0.60
0.14 0.262 0.154 0.370 0.22
0.82 0.317 0.205 0.429 0.91
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markedly glucose intolerance and hyperinsulinemia [31].
In addition, consuming saturated fatty acid diets would
increase LDL cholesterol level in the scavenger receptor
class B type 1 gene variant, a similar effect as CD36 gene
[32]. Our data supported CD36 genetic effects on trigly-
cerides and HDL cholesterol.Evidence for CD36 gene in dyslipidemia
Previous genetic studies showed various effects between
CD36 locus and metabolic syndrome components. A
genome-wide linkage scan among 418 individuals from
27 extended Mexican American families found that two
loci in chromosome 7 were suggested as being linked to
HDL cholesterol and triglycerides levels, besides the
most linkage site in chromosome 15q [33]. In addition,
among non-diabetic Mexican American families, quanti-
tative trait locus study showed a strong linkage of one
metabolic syndrome related factor, HDL and triglycer-
ides, to chromosome 7 (LOD score up to 3.2) [34]; how-
ever, other metabolic factors, including obesity and
blood pressure, cannot be identified to linkage to
chromosome 7, in which CD36 gene exists. Moreover,
another large-scale genome-wide linkage scan among
8664 participants from multiple ethnicities showed that
7q36, a site for CD36, was associated with fasting glu-
cose and insulin resistance [35]. To sum up, a meta-
analysis based on genome-wide linkage studies on quan-
titative lipid traits from the families ascertained from
type 2 diabetes showed that CD36 gene locus (7p11-
q21.11) was significantly linked to triglycerides and tri-
glycerides/HDL cholesterol ratio, but not linked to LDL
or total cholesterol [36]. Our findings also demonstrated
significant association between CD36 gene polymorph-
ism and triglycerides and HDL cholesterol, the traits
predisposing to type 2 diabetes. In another study based
on 1,375 patients with coronary heart disease, one SNP
in CD36, rs3211956, was significantly associated with
acute myocardial infarction as compared with stable cor-
onary disease (allele frequency 11% vs. 8%, p = 0.04) [6].
However, the strength decreased modestly after adjust-
ing covariates and multiple comparisons. Among a co-
hort composed of 675 obese adults (age >40 yrs and
body mass index >25) in the Netherlands, rs1527479, a
C/T SNP in the upstream promoter region in the CD36
gene, homozygous carrier was associated with prevalent
type 2 diabetes, and more so in women and high BMI
(>27) group [8]. Furthermore, the homozygous carriers
were more likely to have a high homeostasis model as-
sessment index value [8]. Another case–control study on
61 CD36-deficient patients and 25 controls showed that
the patients were likely to have a higher type 2 diabetes
prevalence, fasting glucose, glycated hemoglobin andHDL-cholesterol, and likely to have a lower triglyceride
value [4]. In addition, the study based on screening
the coding sequence of the CD36 gene in 272 French
individuals showed that one promoter variant allele
(−178A/C) was associated with adiponectin levels
(p = 0.036 after multiple testing correction) [11]. Among
another French family study, a rare nonsense mutation
(1079 T > G) in CD36 locus showed linkage with familial
type 2 diabetes risk [7]. In addition, genotyping 21 SNPs
in the CD36 gene in 585 non-diabetic Caucasians, Ma
and colleagues showed that 5 tagged SNPs for haplotype
construction [9]. The 30294 G > C polymorphism was
associated with free fatty acid level (p = 0.02) and the
association was apparent among men. Compared with
non-carriers, individuals carrying the haplotype AGGIG
had a 31% higher free fatty acids (p = 0.0002) and 20%
higher triglycerides (p = 0.025) [9]. Furthermore, this
haplotype was associated with a higher risk of coronary
heart disease among type 2 diabetic patients. However,
a survey based on 831 adults from the health screen-
ing showed that one CD36 gene variant (Pro90Ser)
was associated with free fatty acids, but not related to
HDL cholesterol nor triglycerides [12]. Extensive tagged
SNP study on CD36 gene among African-Americans
showed this gene was associated with metabolic syn-
drome and HDL cholesterol [10]. A genome wide associ-
ation study base on more than ten thousand individuals
showed that biological lipoprotein metabolism related
genes, such as CYP7A1, NPC1L1 and SCARB1, were
related to lipid profiles [37]. Our study showed that the
CD36 variants with differential effects on triglycerides
and HDL cholesterol, consistent with previous findings.
Our study has several strengths. First, the study sam-
ple size was moderate, which provided us with sufficient
statistical power. In addition, the selection strategy on
common htSNPs from public domain (HapMap website)
could reduce genotyping costs, and provides an import-
ant tool to explore the candidate gene effects. Second,
this study population is relatively homogenous and thus
may reduce the effect of population stratification. We
recruited the participants from the health checkup cen-
ter in a tertiary university hospital, and these partici-
pants had relatively high socioeconomic status and their
health behavior and health promotion motivation were
high. Third, due to the high prevalence of dyslipidemia
and high blood pressure in the control subjects, we
believe the heterogeneity in the metabolic syndrome
reduced the association strength between gene and
the metabolic syndrome. Further study on the pathogen-
esis of CD36 gene expression and metabolic compo-
nents, especially triglycerides and HDL cholesterol
levels, is warranted.
This study has some limitations. First, some subjects
of the metabolic syndrome may be due to phenocopies
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effects, causing the traits to be the same. This was
apparently due to the relatively middle and elderly parti-
cipants in our study. These phenocopies and misclassifi-
cation would reduce the power of the association and it
may bias our results toward the null. Second, although
our study had sufficient statistical power to detect large
effects resulting from common alleles, the power to
evaluate small effects due to rare alleles or the effect of
interaction was limited. Further gene-environment inter-
action study needs greater study numbers. Studying
complex diseases has been shown to require very large
sample sizes as multiple small effects may be expected.
The study population in this study does exceed many
very small studies, but may still lack power to detect
small associations. Third, we did not include other gen-
etic information, such as APOE, APOA5, and LPL genes.
Indeed, our previous studies have shown that the
APOA5 and APOA1-C3-A4 genetic polymorphism was
associated with dyslipidemia in Taiwanese population
[15,38-40]. Finally, due to different components of the
metabolic syndrome, multiple comparison issues may be
a concern for inflating type I error.
In conclusion, our genetic association study demon-
strated that CD36 gene variants were significantly
associated with triglycerides and HDL-cholesterol levels.
Further study on the pathogenesis of CD36 gene ex-
pression and metabolic components, especially with
regards to triglycerides and HDL cholesterol levels, is
warranted.Additional file
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